Dr. Tyler M. Berzin, MD
Gastroenterology (Gastroenterology Physician)
330 Brookline Ave, Beth Israel Deaconess Medical Center- Harvard Medical
Boston, MA 02215
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 653
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Warren Alpert Medical School of Brown University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MA license 225419
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital - Needham Needham, MA
- Cape Cod Hospital Hyannis, MA
- Beth Israel Deaconess Hospital - Milton Milton, MA
- Anna Jaques Hospital Newburyport, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 653
- Services billed
- 1,192
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Review by radiologist of image from tube placement into bile duct using an endoscope | 117 | 100 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 115 | 106 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 95 | 95 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 85 | 83 |
| Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 73 | 68 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 67 | 64 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 59 | 59 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 48 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 46 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 46 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Boston, MA | 194 |
| Omeprazole Other prescribers in Boston, MA | 90 |
| Pantoprazole Sodium Other prescribers in Boston, MA | 22 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 17 |
| Lansoprazole Other prescribers in Boston, MA | 15 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 15 |
| Lidocaine Hcl Viscous (lidocaine hcl) Other prescribers in Boston, MA | 14 |
| Ciprofloxacin Hcl Other prescribers in Boston, MA | 13 |
| Sucralfate Other prescribers in Boston, MA | 13 |
| Movantik (naloxegol oxalate) Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 33 payments worth $37,145 in total to this clinician.
| Boston Scientific Corporation | $21,246 |
|---|---|
| Amgen Inc. | $7,625 |
| Medtronic, Inc. | $3,894 |
| Olympus Medical Systems Corporation | $2,065 |
| Odin Medical Limited | $1,340 |
| Gyrus Acmi, Inc. | $500 |
| Vascular Technology, Inc. | $350 |
| Sanofi US Services Inc. | $125 |
| Consulting Fee | $34,805 |
|---|---|
| Food and Beverage | $1,267 |
| Travel and Lodging | $723 |
| Honoraria | $350 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_ENDO | $5,200 |
| Amgen Inc. Nov 6, 2025 | Consulting Fee | $3,550 |
| Boston Scientific Corporation Feb 13, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $3,250 |
| Medtronic, Inc. Feb 27, 2025 | Consulting Fee | $3,000 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $2,925 |
| Boston Scientific Corporation Dec 24, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $2,600 |
| Amgen Inc. Aug 6, 2025 | Consulting Fee | $2,538 |
| Olympus Medical Systems Corporation Jun 25, 2025 | Consulting Fee GASTROINTESTINAL VIDEOSCOPE · Gastroenterology | $2,065 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_ENDO | $1,625 |
| Odin Medical Limited Jul 23, 2025 | Consulting Fee | $1,340 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation Dec 24, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $2,600 |
| Boston Scientific Corporation Dec 24, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $1,300 |
| Amgen Inc. Dec 9, 2025 | Consulting Fee | $1,163 |
| Medtronic, Inc. Dec 2, 2025 | Travel and Lodging GI GENIUS · Gastrointestinal AI · travel to Minneapolis, MN · in-kind | $713 |
| Medtronic, Inc. Dec 2, 2025 | Travel and Lodging GI GENIUS · Gastrointestinal AI · travel to Minneapolis, MN · in-kind | $10.00 |
| Amgen Inc. Nov 6, 2025 | Consulting Fee | $3,550 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_ENDO | $5,200 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $2,925 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_ENDO | $1,625 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $1,300 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_ENDO | $650 |
| Amgen Inc. Oct 14, 2025 | Consulting Fee | $375 |
| Gyrus Acmi, Inc. Aug 19, 2025 | Consulting Fee | $500 |
| Amgen Inc. Aug 6, 2025 | Consulting Fee | $2,538 |
| Odin Medical Limited Jul 23, 2025 | Consulting Fee | $1,340 |
| Olympus Medical Systems Corporation Jun 25, 2025 | Consulting Fee GASTROINTESTINAL VIDEOSCOPE · Gastroenterology | $2,065 |
| Vascular Technology, Inc. Jun 19, 2025 | Honoraria | $350 |
| Sanofi US Services Inc. Jun 19, 2025 | Consulting Fee DUPIXENT · Immunology | $125 |
| Medtronic, Inc. Feb 27, 2025 | Consulting Fee | $3,000 |
| Boston Scientific Corporation Feb 13, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $3,250 |
| Boston Scientific Corporation Feb 13, 2025 | Consulting Fee EXALT Model D · EXALT Model D_ENDO | $1,300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $250 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Sanofi US Services Inc. · Active, not recruiting · NCT05731128
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.